Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration
Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…Apomorphine Sublingual Film Versus Subcutaneous Apomorphine in the Treatment of OFF Episodes in Parkinson’s Disease: Results From an Assessment of Patient Satisfaction
Objective: Evaluate treatment satisfaction with apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease (PD).…Widening the phenotype of FXTAS in females: Spasmodic dysphonia in two patients
Objective: We present the cases of two female FXTAS patients who both developed spasmodic dysphonia (SD), also known as laryngeal dystonia. Background: Fragile-X-associated tremor/ataxia syndrome…Changes in botulinum toxin dosing in cervical dystonia over 7 years
Objective: To assess changes in botulinum toxin dosing over the course of illness of cervical dystonia. Background: Muscle specific botulinum toxin injections remains the main…Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms
Objective: Explore the relationship between patient self-reported assessment of positive symptoms, depression, and anxiety in PwPD. Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder…SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.
Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: Evaluate safety and tolerability of apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease…Evolution of biochemical and clinical signature of GBA-related Parkinson’s Disease: a 2-year longitudinal study
Objective: To evaluate peripheral biochemical markers as well as clinical features of GBA-related Parkinson’s Disease (GBA-PD) subjects over a 2-year follow-up in comparison with NM-PD…Exploring the morning akinesia in Parkinson’s disease with the wearable sensor STAT-ON
Objective: To detect the morning akinesia (MA) through the analysis of the gait fluidity (GF) measured by the sensor STAT-ON. Background: The STAT-ON sensor's detection…Comorbidities in Huntington’s disease: An Enroll-HD analysis
Objective: Determine the frequency of comorbidities in people with Huntington’s disease (PwHD) in comparison to non-carrier controls in the Enroll-HD cohort. Background: Despite some publications…
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 153
- Next Page »